Szegedi Tudományegyetem
- Address
- Korányi fasor 8-10, H-6725 Szeged, Hungary
Szegedi Tudományegyetem - Neuroendocrine Tumor Research
Szegedi Tudományegyetem is actively engaged in advancing treatment options for patients with rare and complex malignancies, with particular expertise in gastroenteropancreatic neuroendocrine tumors (GEP-NET). The center participates in international clinical investigations focused on novel therapeutic approaches for unresectable and metastatic neuroendocrine malignancies.
- Advanced neuroendocrine tumor therapeutics
- Gastroenteropancreatic malignancies
- Novel somatostatin analog delivery systems
The research center contributes to pivotal trials evaluating progression-free survival outcomes in patients with well-differentiated GEP-NET, comparing innovative subcutaneous depot formulations against established long-acting release treatments. This work supports the development of improved treatment modalities that may offer enhanced convenience and efficacy for patients with these rare tumor types.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szegedi Tudományegyetem
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Trial of Octreotide Subcutaneous Depot vs. Octreotide LAR or Lanreotide ATG in Unresectable/Metastatic GEP-NET Patients | Camurus AB | Phase III | Not Recruiting | Sep 2021 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lanreotide | 1 | Unknown | 2021-09-27 | 2021-09-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.